Bill > HB2412

This bill requires health benefit plans in Texas, including those issued by various insurance providers, state employee plans, and the Medicaid program, to provide coverage for prescription drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists used to treat obesity. GLP-1 receptor agonists are a class of medications that help manage weight by mimicking a hormone that targets areas of the brain involved in appetite regulation. The bill will apply to health benefit plans delivered, issued, or renewed on or after January 1, 2026, and will take effect on September 1, 2025. If any state agency determines that federal waivers or authorizations are needed to implement the bill, they are permitted to request those waivers and can delay implementation until such authorizations are granted. The legislation aims to expand access to obesity medications by mandating their coverage across a wide range of health insurance plans in the state of Texas.

Business and Industry

https://capitol.texas.gov/BillLookup/History.aspx?LegSess=89R&Bill=HB2412